title: Primary prevention of venous thromboembolism in medical and surgical oncology patients.
abstract: Recent data suggest that patients with a malignancy have a seven-fold increased risk for venous thromboembolism (VTE) compared with those without cancer, suggesting that these patients may benefit from thromboprophylaxis. Mechanisms for the prevention of thromboembolism can be divided into two broad categories: mechanical and pharmacological. Although generally used in combination with pharmacotherapy, little evidence exists for the efficacy of mechanical modalities either in the broader population of patients at risk for VTE or for patients with cancer specifically. A recent study using graduated compression stockings (GCS) for thromboprophylaxis showed no support for the use of stockings in acute stroke patients. Established pharmacological modalities, including warfarin, unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and the factor Xa inhibitor fondaparinux, have been shown to reduce risk for VTE in general medical and surgical populations. In medical cancer patients, only limited data are available for the efficacy of thromboprophylaxis. In contrast, considerable evidence indicates that thromboprophylaxis is warranted in patients undergoing cancer surgery. The most recent evidence suggests that catheter-related thrombosis is not prevented by current pharmacological modalities. On 22 May 2009, a group of clinicians based in the United Kingdom (UK) met in London, UK, to evaluate recent data on cancer thrombosis. This article (the second of four) briefly reviews key data on the prevention of VTE in medical and surgical oncology patients, providing context for a brief transcript of the surrounding discussion and a consensus statement, developed by meeting attendees, on the implications of this information for UK clinical practice.
authors.affiliation: Birmingham Treatment Centre, City Hospital, Dudley Road, Birmingham B18 7QH, UK. andrew.stanley@westmidlands.nhs.uk
authors.forename: A
authors.initials: A
authors.lastname: Stanley
authors.forename: A
authors.initials: A
authors.lastname: Young
mesh_terms: D002405:Catheterization, Central Venous / Q000009:adverse effects; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D017410:Practice Guidelines as Topic; D054556:Venous Thromboembolism / Q000517:prevention & control*
references.citation: Thromb Haemost. 2008 Jan;99(1):38-43
references.pmid: 18217132
references.citation: JAMA. 2006 Dec 6;296(21):2558-60
references.pmid: 17148721
references.citation: Thromb Haemost. 1995 Oct;74(4):1055-8
references.pmid: 8560413
references.citation: Lancet. 2007 Sep 15;370(9591):949-56
references.pmid: 17869635
references.citation: BMJ. 2006 Feb 11;332(7537):325-9
references.pmid: 16439370
references.citation: N Engl J Med. 2002 Mar 28;346(13):975-80
references.pmid: 11919306
references.citation: J Clin Oncol. 2006 Mar 1;24(7):1112-8
references.pmid: 16505431
references.citation: N Engl J Med. 1999 Sep 9;341(11):793-800
references.pmid: 10477777
references.citation: JAMA. 2005 Feb 9;293(6):715-22
references.pmid: 15701913
references.citation: Blood. 2002 Sep 15;100(6):2272-3
references.pmid: 12229885
references.citation: J Bone Joint Surg Br. 2009 May;91(5):636-44
references.pmid: 19407299
references.citation: Chest. 2008 Jun;133(6 Suppl):381S-453S
references.pmid: 18574271
references.citation: J Clin Oncol. 2007 Dec 1;25(34):5490-505
references.pmid: 17968019
references.citation: Lancet. 2009 May 16;373(9676):1673-80
references.pmid: 19411100
references.citation: N Engl J Med. 2008 Jun 26;358(26):2776-86
references.pmid: 18579812
references.citation: Chest. 2008 Jun;133(6 Suppl):141S-159S
references.pmid: 18574264
references.citation: Ann Surg. 1988 Aug;208(2):227-40
references.pmid: 2456748
references.citation: Lancet. 1994 Apr 9;343(8902):886-9
references.pmid: 7908358
references.citation: Arch Intern Med. 2000 Mar 27;160(6):809-15
references.pmid: 10737280
references.citation: J Thromb Haemost. 2007 Nov;5(11):2178-85
references.pmid: 17764540
references.citation: J Clin Oncol. 2000 Sep;18(17):3078-83
references.pmid: 10963635
references.citation: Oncologist. 2003;8(4):381-8
references.pmid: 12897335
references.citation: Arch Intern Med. 2006 Feb 27;166(4):458-64
references.pmid: 16505267
references.citation: Blood. 2001 Sep 1;98(5):1614-5
references.pmid: 11520815
references.citation: Oncologist. 2005 Jan;10(1):72-9
references.pmid: 15632254
references.citation: J Thromb Haemost. 2005 Jan;3(1):28-34
references.pmid: 15634263
references.citation: Ann Oncol. 2008 May;19 Suppl 2:ii126-7
references.pmid: 18456750
references.citation: J Clin Oncol. 2006 Jan 20;24(3):431-6
references.pmid: 16365178
references.citation: Am J Med. 2007 Oct;120(10):901.e1-13
references.pmid: 17904462
references.citation: Blood. 2002 Nov 15;100(10):3484-8
references.pmid: 12393647
references.citation: Br J Surg. 2005 Oct;92(10):1212-20
references.pmid: 16175516
references.citation: Lancet. 2009 Jun 6;373(9679):1958-65
references.pmid: 19477503
references.citation: Curr Opin Investig Drugs. 2008 Sep;9(9):1020-33
references.pmid: 18729009
references.citation: Chest. 2004 Sep;126(3 Suppl):311S-337S
references.pmid: 15383477
references.citation: Ann Surg Oncol. 2007 Feb;14(2):929-36
references.pmid: 17103259
references.citation: J Clin Oncol. 2004 May 15;22(10):1944-8
references.pmid: 15143088
references.citation: Lancet. 2009 Feb 14;373(9663):567-74
references.pmid: 19217991
references.citation: Thromb Haemost. 2009 Apr;101(4):780-2
references.pmid: 19350128